References
- Inflation Reduction Act 2022. [cited 2022 Oct 6]. https://www.congress.gov/bill/117th-congress/house-bill/5376/text
- Dakin H, Devlin N, Feng Y, et al. The influence of cost-effectiveness and other factors on NICE decisions. Health Econ. 2015;24(10):1256–1271. doi: 10.1002/hec
- Rodwin MA. Pharmaceutical price and spending controls in France: lessons for the United States. Int J Heal Serv. 2020;50(2):156–165. doi: 10.1177/0020731419897580
- Rodwin MA, Gerke S. German Pharmaceutical pricing: lessons for the United States. Int J Heal Serv. 2021;51(3):379–391. doi: 10.1177/00207314211040948
- Seshamani M. Medicare drug price negotiation program: revised guidance, implementation of sections 1191 – 1198 of the Social security Act for initial price applicability Year 2026. [cited 2023 Aug 14].
- Shafrin J, Lakdawalla DN, Doshi JA, et al. A strategy for value-based drug pricing under the inflation reduction Act. Heal Aff Forefr. 2023. doi: 10.1377/forefront.20230503.153705
- Sullivan SD, Lakdawalla DN, Devine B, et al. Alternatives to the QALY for comparative effectiveness Research. Heal Aff Forefr. 2023. doi: 10.1377/forefront.20230419.896238
- Ollendorf DA, Voehler D. Options for CMS drug price negotiations. Heal Aff Forefr. 2023. doi: 10.1377/forefront.20221222.40991
- National Council on Disability (NCD). Alternatives to QALY-Based cost-effectiveness analysis for determining the value of prescription drugs and other health interventions. (WA) DC; 2022. https://ncd.gov/sites/default/files/NCD_Alternatives_to_the_QALY_508.pdf
- Carlson JJ, Brouwer ED, Kim E, et al. Alternative approaches to quality-adjusted life-year estimation within standard cost-effectiveness models: literature review, feasibility assessment, and impact evaluation. Value Heal. 2020;23(12):1523–1533. doi: 10.1016/j.jval.2020.08.2092
- Rand LZ, Melendez-Torres G, Kesselheim AS. Alternatives to the quality-adjusted life year: how well do they address common criticisms? Health Serv Res. 2023;58(2):433–444. doi: 10.1111/1475-6773.14116
- Lakdawalla DN, Phelps CE. Health technology assessment with diminishing returns to health: the generalized Risk-adjusted cost-effectiveness (GRACE) approach. Value Heal. 2021;24(2):244–249. doi: 10.1016/j.jval.2020.10.003
- DiStefano MJ, Krubiner CB. Beyond the numbers: a critique of quantitative multi-criteria decision analysis. Int J Technol Assess Health Care. 2020;36(4):292–296. doi: 10.1017/S0266462320000410
- Institute for Clinical and Economic Review. The QALY: rewarding the care that most improves patients’ lives. [cited 2023 Aug 1]. https://icer.org/wp-content/uploads/2020/12/QALY_evLYG_FINAL.pdf. Published 2018.
- Campbell JD, Whittington MD, Pearson SD An alternative measure of health for value assessment: the equal value life-year. Pharmacoeconomics. 2023. doi:10.1007/s40273-023-01302-6
- Basu A, Carlson J, Veenstra D. Health years in total: a New health objective function for cost-effectiveness analysis. Value Heal. 2020;23(1):96–103. doi: 10.1016/j.jval.2019.10.014
- Lakdawalla DN, Phelps CE. A guide to extending and implementing generalized risk-adjusted cost-effectiveness (GRACE). Eur J Heal Econ. 2022;23(3):433–451. doi: 10.1007/s10198-021-01367-0
- Phelps CE, Lakdawalla DN. Methods to adjust willingness-to-pay measures for severity of illness. Value Heal. 2023;26(7):1003–1010. doi: 10.1016/j.jval.2023.02.001
- Lakdawalla D, Phelps C. The generalized Risk-adjusted cost-effectiveness (GRACE) model for measuring the value of gains in health: an exact formulation. J Benefit Cost Anal. 2023;14(1):44–67. doi: 10.1017/bca.2023.6
- McQueen RB, Slejko JF. Toward modified impact inventory tables to facilitate patient‑centered value assessment. PharmacoEconomics. 2021;39(4):379–382. doi: 10.1007/s40273-021-01017-6
- McQueen RB, Mendola ND, Jakab I, et al. Framework for patient experience value elements in rare disease: a case study demonstrating the applicability of combined qualitative and quantitative Methods. Pharmacoecon Open. 2022;7(2):217–228. doi: 10.1007/s41669-022-00376-w
- Thokala P, Devlin N, Marsh K, et al. Multiple criteria decision analysis for health care decision making - an introduction: report 1 of the ISPOR MCDA emerging good practices task force. Value Heal. 2016;19(1):1–13. doi: 10.1016/j.jval.2015.12.003
- Marsh K, Ijzerman M, Thokala P, et al. Multiple criteria decision analysis for health care decision making — emerging good practices: report 2 of the ISPOR MCDA emerging good practices task force. Value Heal. 2016;19(2):125–137. doi: 10.1016/j.jval.2015.12.016
- Baltussen R, Marsh K, Thokala P, et al. Multicriteria decision analysis to support health technology assessment agencies: benefits, limitations, and the way forward. Value Heal. 2019;22(11):1283–1288. doi: 10.1016/j.jval.2019.06.014
- Towse A, Barnsley P Clarifying meanings of absolute and proportional shortfall with examples. [cited 2023 Aug 1]. https://www.nice.org.uk/Media/Default/About/what-we-do/NICE-guidance/NICE-technology-appraisals/OHE-Note-on-proportional-versus-absolute-shortfall.pdf. Published 2013.
- Reckers-Droog V, van Exel J, Brouwer W. Equity weights for priority setting in healthcare: severity, age, or both? Value Heal. 2019;22(12):1441–1449. doi: 10.1016/j.jval.2019.07.012
- Magnussen J Severity of illness and priority setting in Norway. [cited 2023 Aug 1]. https://www.regjeringen.no/contentassets/d5da48ca5d1a4b128c72fc5daa3b4fd8/summary_the_magnussen_report_on_severity.pdf. Published 2015.
- McQueen RB, Inotai A, Zemplenyi A, et al. Multi-stakeholder perceptions of broader contextual value elements for United States value assessment of health interventions. Value Heal. 2023. In press. doi: 10.1016/j.jval.2023.09.2910
- Nord E, Pinto JL, Richardson J, et al. Incorporating societal concerns for fairness in numerical valuations of health programmes. Health Econ. 1999;8(1):25–39. doi: 10.1002/(SICI)1099-1050(199902)8:1<25:AID-HEC398>3.0.CO;2-H
- 118th Congress. H.R.485 - protecting health care for all patients Act of 2023.
- Krubiner CB, Tugendhaft A, DiStefano MJ, et al. The value of explicit, deliberative, and context-specified ethics analysis for health technology assessment: evidence from a novel approach piloted in South Africa. Value Heal Reg Issues. 2023;34:23–30. doi: 10.1016/j.vhri.2022.10.003
- Damschroder LJ, Zikmund-Fisher BJ, Ubel PA. Considering adaptation in preference elicitations. Heal Psychol. 2008;27(3):394–399. doi: 10.1037/0278-6133.27.3.394
- CMS. Medicare drug price negotiation program patient-focused listening sessions. [cited 2023 Aug 9]. https://www.cms.gov/inflation-reduction-act-and-medicare/medicare-drug-price-negotiation-program-patient-focused-listening-sessions. Published 2023.